Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) FCF Margin (2018 - 2023)

Historic FCF Margin for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to 7058.48%.

  • Denali Therapeutics' FCF Margin fell 52856300.0% to 7058.48% in Q3 2023 from the same period last year, while for Jun 2024 it was 31736.31%, marking a year-over-year decrease of 316426900.0%. This contributed to the annual value of 112.22% for FY2023, which is 1298400.0% up from last year.
  • Per Denali Therapeutics' latest filing, its FCF Margin stood at 7058.48% for Q3 2023, which was down 52856300.0% from 39.35% recorded in Q2 2023.
  • Denali Therapeutics' 5-year FCF Margin high stood at 161.84% for Q4 2020, and its period low was 7058.48% during Q3 2023.
  • Moreover, its 5-year median value for FCF Margin was 669.44% (2021), whereas its average is 946.05%.
  • The largest annual percentage gain for Denali Therapeutics' FCF Margin in the last 5 years was 27402000bps (2019), contrasted with its biggest fall of -59237900bps (2019).
  • Over the past 5 years, Denali Therapeutics' FCF Margin (Quarter) stood at 1079.11% in 2019, then surged by 115bps to 161.84% in 2020, then tumbled by -438bps to 547.76% in 2021, then crashed by -38bps to 753.79% in 2022, then tumbled by -836bps to 7058.48% in 2023.
  • Its FCF Margin was 7058.48% in Q3 2023, compared to 39.35% in Q2 2023 and 184.62% in Q1 2023.